Biopharma transaction volumes remained resilient last year despite lesser dealmaking activity across the industry. That deal volume is expected to continue in 2024 as patents expire between 2025-2030, putting large pharmaceutical companies’ revenues at risk and positioning them to fill their pipelines by acquiring late- or commercial-stage biotechs. Dealmaking is already off to a hot start this year. Johnson & Johnson (NYSE: JNJ) announced it will acquire Ambrx (NASDAQ: AMAM), a clinical-stage biopharma company with a platform to develop antibody-drug conjugates (ADCs, which are cancer-killing medicines), for $2 billion. GSK (NYSE: GSK) announced it will acquire asthma drug maker Aiolos Bio for $1.4 billion.
Read the full article: Upcoming Patent Expirations to Drive Biopharma Deals //
Source: https://www.themiddlemarket.com/news-analysis/upcoming-patent-expirations-to-drive-biopharma-deals